New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 2, # 9/10 - January/Februrary, 1997

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
BREAST CANCER­PART V
Novel Drugs in Development
New Hormonal Therapies 450
  Non-steroidal Anit-estrogens 474
    Toremifene 474
    Droloxifene 474
    Idoxifene 474
    Raloxifene 475
  Steroidal (Pure) Anti-estrogens 475
    ICI 182, 780 475
  Anti-progestins 475
    Mifepristone 476
    RTI-3021-020 476
    LG2527 and LG2716 476
  Aromatase Inhibitors 474
    Exemestane 476
  Luteinizing Hormone-releasing Hormone (LHRH) Agonists 476
  Other Developments 477
    D3967 477
    Fluasterone 477
Growth Factor Modulation 477
  Polyamine Depletion 477
  Epidermal Growth Factor (EGF) Blockade 477
    Abgenix 477
    ImClone Systems 478
New Chemotherapeutics 478
  Gemcitabine 478
  Anthracyclines-Novel Approaches and Analogs 479
    Liposomal encapsulation 479
    Annamycin 479
    Anthrapyrazoles 479
    Other anthracycline analogs 479
  Anthracyclines-Novel Delivery Approaches 479
    Atrix Laboratories 479
    Britsol-Myers Squibb 480
    Genentech 480
  5-fluorouracil Analogs/Thymidylate Synthase Inhibitors 479
    776C85 480
    Capecitabine 481
    Ralitrexed 481
    S-1 481
    UFT 481
  Topoisomerase I inhibitors 481
  Taxanes 481
  Retinoids 482
    LGD1069 482
    Interferon/retinoid combinations 482
    Vitamin D derivatives 482
    Fenretinide 482
  Metalloprotease Inhibitors 482
Alteration/Repair of Oncogenes/Tumor Suppressor Genes and Related Pathways 482
  p53 482
    Canji 483
    Genzyme Molecular Oncology 483
    Introgen Therapeutics 483
    Onyx Pharmaceuticals 483
  Her2/neu 482
    Targeted Genetics 483
  Cell Cycle Regulation 484
    Cascade Oncogenetics 484
    Mitotix 485
Cell Modification Using Gene Transfer 485
  Prevention of Myelosuppression 485
    Ingenex 485
  Enhancement/Sensitization of Chemotherapy 485
    GenVec 486
Immunotherapy/Vaccines 486
  Theratope 486
  CEA-based Vaccines 486
    Applied Immune Sciences 486
    Therion Biologics 486
  MUC-1-based Vaccines 487
    Biomira 487
  Gene Transfer/Immunotherapy 487
    Cell Genesys 487
  Immunomodulation 488
    AntiCancer 488
    Daiwa Pharmaceutical 488
    Ergo Science 488
  Other Strategies 485
Monoclonal Antibodies and Immunoconjugates/Immunotoxins 489
  MAbs Against HER2/neu 489
    Genentech 489
    Amgen 489
  Biospecific MAbs 489
    Medarex 489
    Chiron 490
  Recombinant Immunotoxins 490
    BR96 sFv-PE40 491
    Immunotoxin LMB-1 491
    Immunotoxin-LMB7 491
    ScFv2(FRP5/225)-ETA and ScFv(FRP5)-TGF alpha-ETA 491
    AR209 491
    CP-IL4-toxin 491
Natural Products 491
  Novel Therapeutic Agents 492
    Paracelsian 492
    PharmaMar 492
  Chemoprevention 492
    Monoterpenes 492
    Genistein 493
    Resveratol 493
Angiogenesis/Anti-vascular Approaches 493
  Angiogenesis Inhibition 493
    Laboratoires Aeterna 493
  Anti-vascular Approaches 493
Photodynamic Therapy 494
  PDT in Combination with Chemotherapeutics 494
  PDT and Immunotherapy Approaches 494
    Xytonix 494
  PDT and Anti-angiogenesis Approaches 495

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887